A5025815003- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Biosimilars and Bioanalytical Methods
- Spondyloarthritis Studies and Treatments
- Pregnancy and Medication Impact
- SARS-CoV-2 and COVID-19 Research
- Psoriasis: Treatment and Pathogenesis
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Reproductive System and Pregnancy
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Long-Term Effects of COVID-19
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Monoclonal and Polyclonal Antibodies Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Pharmaceutical studies and practices
- Dermatological and COVID-19 studies
- Musculoskeletal Disorders and Rehabilitation
- Viral Infections and Immunology Research
- Health and Medical Studies
- Endometriosis Research and Treatment
- Systemic Sclerosis and Related Diseases
German Rheumatism Research Centre
2016-2025
Charité - Universitätsmedizin Berlin
2011-2025
Humboldt-Universität zu Berlin
2025
Freie Universität Berlin
2025
MRC Epidemiology Unit
2017-2023
Leibniz Association
2010-2023
Sorbonne Université
2023
Pitié-Salpêtrière Hospital
2023
Medical University of Vienna
2023
Jeju National University Hospital
2023
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated hospitalisation status disease.Case series of individuals disease from the Global Rheumatology Alliance registry: 24 March 2020 20 April 2020. Multivariable logistic regression used estimate ORs 95% CIs hospitalisation. Age, sex, smoking status, diagnosis, comorbidities medications taken immediately prior infection were analysed.A total 600 cases 40...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
Abstract Objective To estimate the incidence rates of serious and nonserious infections in patients with rheumatoid arthritis (RA) who start treatment a biologic agent, to compare these those RA receive conventional treatment. Methods Patients enrolled German biologics register between May 2001 September 2003 were included. Treating rheumatologists assessed adverse events events. All experienced within 12 months after study entry analyzed. Propensity score methods applied which part rate...
To determine factors associated with COVID-19-related death in people rheumatic diseases.
The risk of bacterial infection is increased in patients treated with drugs that inhibit tumor necrosis factor alpha (TNF-alpha). Little known about the reactivation latent viral infections during treatment TNF-alpha inhibitors.To investigate whether inhibitors together as a class, or separately either monoclonal anti-TNF-alpha antibodies (adalimumab, infliximab) fusion protein (etanercept), are related to higher rates herpes zoster rheumatoid arthritis.Patients were enrolled German...
<h3>Objective</h3> To examine the risk of serious infection conveyed by tumour necrosis factor α (TNFα) inhibitors in treatment rheumatoid arthritis (RA). <h3>Methods</h3> Data from patients with RA enrolled German biologics register RABBIT were used for analysis. Baseline patient characteristics, time-varying factors (treatment changes, functional capacity) and selection processes caused dropout, death or switching to non-anti-TNF taken into account estimate adjusted incidence rate ratios...
To investigate the impact of disease activity, course disease, its treatment over time, comorbidities and traditional risk factors on survival.Data German biologics register RABBIT were used. Cox regression was applied to time-varying covariates (disease activity as measured by DAS28, functional capacity, with glucocorticoids, biologic or synthetic modifying antirheumatic drugs (DMARDs)) mortality after adjustment for age, sex, comorbid conditions smoking.During 31 378 patient-years...
Individuals with inflammatory rheumatic disease require special consideration regard to coronavirus 2019 (COVID-19), caused by the severe acute respiratory syndrome 2 (SARS-CoV-2). Many of these individuals are considered at-risk for serious infections due their immunocompromised state resulting from underlying immune conditions and use targeted immune-modulating therapies such as biologics.1–4 However, some disease-modifying drugs commonly used treat diseases, hydroxychloroquine, being...
To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).We analysed the Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD for RA at clinical onset (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 (IL-6i) tumour necrosis factor (TNFi, reference group). The ordinal severity...
Objective To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated tocilizumab (TCZ). Methods In 13 310 RA observed German biologics register R heumatoid A rthritis: O b servation Bi ologic T herapy, 141 serious gastrointestinal events possibly associated were reported until 31 October 2015. All validated independently by two physicians, blinded for treatment exposure. Results 37 LIPs (32 colon/sigma) 53 972 patient years...
<h3>Objectives</h3> Some studies have reported a possible association between exposure to tumour necrosis factor (TNF) inhibitors and an increased risk of melanoma. The aim this study was investigate the incidence invasive cutaneous melanomas in patients with rheumatoid arthritis (RA) treated TNF (TNFi), other biologic disease modifying drugs non-biologic therapy. <h3>Methods</h3> Eleven registers from nine European countries participated collaborative project. According predefined...
To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).Physician-reported registry I-RMD non-inflammatory RMD (NI-RMDs) patients vaccinated SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, diagnosis, activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) breakthrough infections. Data were analysed descriptively.The study included...
Introduction Whether patients with inflammatory rheumatic and musculoskeletal diseases (RMD) are at higher risk to develop severe courses of COVID-19 has not been fully elucidated. Aim this analysis was describe RMD according their severity identify factors for hospitalisation. Methods Patients PCR confirmed SARS-CoV-2 infection reported the German registry from 30 March 1 November 2020 were evaluated. Multivariable logistic regression used estimate ORs hospitalisation due COVID-19. Results...
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare effectiveness four current second-line therapies RA with different modes action, since JAKi approval, an international collaboration 19 registers. Methods In this observational cohort study, patients initiating tumour necrosis factor inhibitors (TNFi), interleukin-6 (IL-6i), abatacept (ABA) or were included. compared these treatments terms...
<h3>Aim</h3> To determine characteristics associated with more severe outcomes in a global registry of people systemic lupus erythematosus (SLE) and COVID-19. <h3>Methods</h3> People SLE COVID-19 reported the Global Rheumatology Alliance from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised no oxygenation, (3) any ventilation or oxygenation (4) death. A multivariable logistic regression model constructed assess relationship...
Abstract Introduction We used the data of German biologics register RABBIT, a nationwide prospective cohort study, to investigate risk new or recurrent malignancy in patients with rheumatoid arthritis (RA) receiving compared conventional disease modifying anti-rheumatic drugs (DMARDs). Methods The analysis was based on RA enrolled RABBIT at start biologic DMARD therapy between 01 May 2001 and 31 December 2006. Incidences first malignancies were analysed separately. A nested case-control...
Abstract Objective Randomized clinical trials (RCTs) evaluate the efficacy of treatments in selected groups patients defined by strict inclusion criteria. The value these predicting therapeutic effectiveness “real world” is limited. This observational cohort study was designed to complement knowledge obtained RCTs evaluating tumor necrosis factor (TNF) inhibitors with rheumatoid arthritis (RA) according their eligibility for major trials. Methods Using data from German biologics register...
Abstract Objective To determine the hazard risk of developing or worsening heart failure in rheumatoid arthritis (RA) patients treated with tumor necrosis factor α (TNFα) inhibitors. Methods RA ages 18–75 years who started treatment infliximab, etanercept, adalimumab (n = 2,757), conventional disease‐modifying antirheumatic drugs (controls; n 1,491) at time enrollment a German biologics register were studied. Cox proportional hazards models applied to investigate influence disease‐related...
Abstract We investigated the frequency of remission according to disease activity score (DAS28) definition, modified American Rheumatology Association (ARA) criteria, and an achievement a functional status above defined thresholds ('functional remission', 'physical independence') in rheumatoid arthritis (RA) patients treated with either biologics or conventional DMARDs. used data prospective cohort study, German register RABBIT (German acronym for Rheumatoid Arthritis – Observation Biologic...
<h3>Objective</h3> To evaluate the Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) Risk Score for serious infections in patients with rheumatoid arthritis (RA). <h3>Methods</h3> The RABBIT was developed 2011 on a cohort RA enrolled German biologics register between 2001 and 2007. this score, we used data from after 1 January 2009. Expected numbers expected at least one infection per year were calculated by means compared observed evaluation sample. <h3>Results</h3> score an...
This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on outcomes serious infections (SIs) in patients with rheumatoid arthritis.We SIs observed 947 enrolled German biologics register RABBIT(Rheumatoid arthritis: observation biologic therapy). Outcomes were (1) recovery without complication, (2) sepsis following SI (≤30 days), and (3) death after known (≤90 days). We applied a multinomial generalised estimating equation model...
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...